Apellis Pharmaceuticals Inc (APLS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.98 is considered Undervalued compared with the five-year average of -26.92. The fair price of Apellis Pharmaceuticals Inc (APLS) is between 52.68 to 56.82 according to relative valuation method. Compared to the current price of 20.70 USD , Apellis Pharmaceuticals Inc By Undervalued By 60.7%.

Relative Value

Fair Zone

52.68-56.82

Current Price：20.70

60.7%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Apellis Pharmaceuticals Inc (APLS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Apellis Pharmaceuticals Inc (APLS) has a current Price-to-Book (P/B) ratio of 8.15. Compared to its 3-year average P/B ratio of 19.75, the current P/B ratio is approximately -58.70% higher. Relative to its 5-year average P/B ratio of 15.95, the current P/B ratio is about -48.87% higher. Apellis Pharmaceuticals Inc (APLS) has a Forward Free Cash Flow (FCF) yield of approximately 2.40%. Compared to its 3-year average FCF yield of -6.24%, the current FCF yield is approximately -138.54% lower. Relative to its 5-year average FCF yield of -7.13%, the current FCF yield is about -133.70% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for APLS competitors is 34.72, providing a benchmark for relative valuation. Apellis Pharmaceuticals Inc Corp (APLS.O) exhibits a P/S ratio of 3.98, which is -88.53% above the industry average. Given its robust revenue growth of -5.94%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of APLS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of APLS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is APLS currently overvalued or undervalued?

Apellis Pharmaceuticals Inc (APLS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.98 is considered Undervalued compared with the five-year average of -26.92. The fair price of Apellis Pharmaceuticals Inc (APLS) is between 52.68 to 56.82 according to relative valuation method. Compared to the current price of 20.70 USD, Apellis Pharmaceuticals Inc is Undervalued By 60.70%.

What is Apellis Pharmaceuticals Inc (APLS) fair value?

APLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Apellis Pharmaceuticals Inc (APLS) is between 52.68 to 56.82 according to relative valuation method.

How does APLS's valuation metrics compare to the industry average?

The average P/S ratio for APLS's competitors is 34.72, providing a benchmark for relative valuation. Apellis Pharmaceuticals Inc Corp (APLS) exhibits a P/S ratio of 3.98, which is -88.53% above the industry average. Given its robust revenue growth of -5.94%, this premium appears unsustainable.

What is the current P/B ratio for Apellis Pharmaceuticals Inc (APLS) as of Mar 02 2026?

As of Mar 02 2026, Apellis Pharmaceuticals Inc (APLS) has a P/B ratio of 8.15. This indicates that the market values APLS at 8.15 times its book value.

What is the current FCF Yield for Apellis Pharmaceuticals Inc (APLS) as of Mar 02 2026?

As of Mar 02 2026, Apellis Pharmaceuticals Inc (APLS) has a FCF Yield of 2.40%. This means that for every dollar of Apellis Pharmaceuticals Inc's market capitalization, the company generates 2.40 cents in free cash flow.

What is the current Forward P/E ratio for Apellis Pharmaceuticals Inc (APLS) as of Mar 02 2026?

As of Mar 02 2026, Apellis Pharmaceuticals Inc (APLS) has a Forward P/E ratio of -17.57. This means the market is willing to pay $-17.57 for every dollar of Apellis Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Apellis Pharmaceuticals Inc (APLS) as of Mar 02 2026?

As of Mar 02 2026, Apellis Pharmaceuticals Inc (APLS) has a Forward P/S ratio of 3.98. This means the market is valuing APLS at $3.98 for every dollar of expected revenue over the next 12 months.

APLS Valuation